Table 2.
Proportions and percentage of drug-resistant GNB recovered from clinical samples of patients in ICU.
| Antimicrobial Drugs |
PA | KN | EC | AB | SM | ECl | OGNB | Overall Isolates |
|---|---|---|---|---|---|---|---|---|
| Ampicillin | 101/104 (97.12) |
78/83 (93.98) | 30/32 (93.75) | 22/22 (100) |
231/241 (95.85) |
|||
| Ampicillin/ Sulbactam |
71/104 (68.27) | 64/83 (77.11) | 28/53 (52.83) | 24/32 (75.00) | 13/29 (44.83) |
200/301 (66.67) |
||
| Piperacillin | 12/17 (70.59) | 30/30 (100) |
20/25 (80.00) |
6/8 (75.00) |
0/2 (0.00) |
68/82 (82.93) |
||
| Piperacillin/ Tazobactam |
71/155 (45.80) | 28/103 (27.18) | 28/81 (34.57) | 8/32 (25.00) | 4/22 (18.18) |
139/393 (35.36) |
||
| Ticarcillin/ Clavulanic acid |
26/40 (65.00) | 11/28 (39.29) |
16/29 (55.17) |
16/28 (57.14) | 10/28 (35.71) | 4/7 (57.14) |
2/14 (14.29) |
85/174 (48.85) |
| Cefazolin | 25/41 (60.97) | 34/411 (82.93) | 8/8 (100) | 8/10 (80.00) |
75/100 (75.00) |
|||
| Cefotetan | 7/62 (11.29) | 1/57 (1.75) |
6/16 (37.50) | 2/11 (18.18) |
16/146 (10.96) |
|||
| Cefuroxime | 84/103 (81.55) | 73/83 (87.95) | 27/32 (84.98) | 18/22 (81.82) |
202/240 (84.17) |
|||
| Cefotaxime | 84/104 (80.76) | 72/83 (86.75) | 40/53 (75.47) | 22/32 (68.75) | 17/29 (58.62) |
235/301 (78.07) |
||
| Ceftazidime | 100/154 (64.93) | 84/104 (80.76) | 73/83 (87.95) | 43/53 (81.13) | 28/49 (57.14) | 22/32 (68.75) | 24/36 (66.67) |
374/511 (73.19) |
| Ceftriaxone | 84/104 (80.76) | 73/83 (87.95) | 36/53 (67.92) | 23/32 (71.88) | 17/29 (58.62) |
233/301 (77.41) |
||
| Cefepime | 83/155 (55.13) | 83/104 (79.80) | 71/83 (85.54) | 40/53 (75.47) | 19/32 (59.37) | 17/29 (58.62) |
313/456 (68.64) |
|
| Aztreonam | 24/57 (42.11) | 65/74 (87.84) | 56/63 (88.89) | 14/16 (87.50) | 8/12 (66.67) |
167/222 (75.23) |
||
| Imipenem | 108/155 (69.68) | 10/104 (9.62) | 3/83 (3.61) | 7/32 (21.88) | 2/15 (13.33) |
130/389 (33.41) |
||
| Meropenem | 84/155 (54.19) | 7/104 (6.73) | 2/83 (2.41) | 30/53 (56.60) | 1/32 (3.13) | 3/36 (8.33) |
127/463 (27.42) |
|
| Ciprofloxacin | 65/155 (41.93) | 32/104 (30.77) | 65/83 (78.31) | 42/53 (79.25) | 16/32 (50.00) | 8/29 (27.59) |
228/456 (49.34) |
|
| Levofloxacin | 61/155 (39.35) | 16/104 (15.38) | 63/83 (75.90) | 32/53 (60.38) | 3/49 (6.12) | 4/32 (12.50) | 7/36 (19.44) |
186/512 (36.32) |
| Moxifloxacin | 5/28 (17.86) | 21/30 (70.00) | 1/8 (12.50) | 1/9 (11.11) |
28/75 (37.33) |
|||
| Amikacin | 90/155 (58.06) | 14/104 (13.46) | 8/83 (9.64) | 31/53 (58.49) | 5/32 (15.63) | 10/29 (34.48) |
158/456 (34.65) |
|
| Gentamicin | 80/155 (51.61) |
48/104 (46.15) | 52/83 (62.65) | 45/53 (84.91) | 9/32 (28.13) | 8/29 (27.59) |
242/456 (53.07) |
|
| Tobramycin | 66/155 (42.58) | 63/102 (61.76) | 64/81 (79.01) | 34/53 (64.15) | 15/31 (48.39) | 18/29 (62.07) |
260/451 (57.65) |
|
| Trimethoprim/ Sulfamethoxazole |
66/102 (64.71) | 52/82 (63.41) | 41/53 (77.36) | 4/49 (8.16) | 15/31 (48.39) | 15/35 (42.86) |
193/352 (54.83) |
Data that were available in Microbiology Laboratory reports were informed. PA: P. aeruginosa; KP: K. pneumoniae; EC: E. coli; AB: A. baumannii; SM: S. maltophilia; ECl: E. cloacae; OGNB: Other GNB. OGNB include: P. mirabilis (n = 9). S. marcescens (n = 9), Burkholderia spp. (n = 9), A. lwoffi (n = 8), and K. oxytoca (n = 5).